| Status | Awaiting development |
| Technology type | Medicine |
| Decision | None selected |
| Process | TAG |
| ID number | 3851 |
Provisional Schedule
| Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | 25 April 2022 - 23 May 2022 |
| Expected publication | 10 May 2023 |
Project Team
| Project lead | Kate Moore |
Email enquiries
- If you have any queries please email TATeam5@nice.org.uk
| External Assessment Group | Kleijnen Systematic Reviews Ltd |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 26 November 2021 | Following a request received from the company, NICE will be undertaking an appraisal of Dabrafenib with trametinib for treating advanced BRAF V600 mutation-positive non-small-cell lung cancer. This was originally terminated guidance TA564. The appraisal is expected to start during April 2022 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during mid-June 2022. The deadline for submissions is expected in approximately mid-August 2022. |
For further information on our processes and methods, please see our CHTE processes and methods manual